Pair page
BPC-157 with IGF-1 DES
Mechanism-tag overlap and published literature for BPC-157 and IGF-1 DES, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cytoprotectiontissue-repair
igf-1-receptor-agonistmodified-proteinn-terminally-truncated-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 and IGF-1 DES have published these mechanism-level observations. Not a co-administration recommendation.
IGF-1 DES provides a local growth signal (PI3K-Akt, satellite cell activation, protein synthesis); BPC-157 provides tissue repair and angiogenesis signaling (VEGFR2-eNOS, FAK-paxillin). At an injury site, the combination creates a locally concentrated repair environment with complementary mechanisms. Common in aggressive injury-recovery community protocols; no human controlled evidence for the combination.
Quick facts
BPC-157
IGF-1 DES
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
| 2002 | IGF-1 DES | Philipps AF, Kling PJ, Grille JG, Dvoráková S. Intestinal transport of insulin-like growth factor-I (IGF-I) in the suckling rat. J Pediatr Gastroenterol Nutr. 2002;35(4):539-544. PMID: 12394383. (Colostrum IGF-1 DES context.) PMID 12394383 | preclinical, in vivo |
| 1993 | IGF-1 DES | Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. PMID: 8371077. (In vivo anabolic effects of IGF-1 DES vs native IGF-1.) PMID 8371077 | preclinical, in vivo |
| 1991 | IGF-1 DES | Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, Ferraiolo BL. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), des(1-3)IGF-I and IGF-II in rats. J Endocrinol. 1991;131(1):87-93. PMID: 1720984. PMID 1720984 | preclinical, in vivo |
| 1991 | IGF-1 DES | Williams ED, et al. Comparison of des(1-3)IGF-1 and IGF-1 in promoting wound healing. Growth Factors. 1991 context. (Wound-healing preclinical reference.) | preclinical, in vivo |
| 1989 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Bergman T, Jörnvall H, Roberts PJ, Crawford M, Håkansson LN, Civalero I, Nordberg A. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Bioche… PMID 2597159 | mechanism / discovery |
| 1988 | IGF-1 DES | Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. 1988;251(1):95-103. PMID: 3401742. (Seminal characterization of IGFBP-… PMID 3401742 | mechanism / discovery |
| 1986 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Andersson C, Hall E, Sjögren B, Holmgren A, Jörnvall H. Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc Natl Acad Sci USA. 1986;83(13):4904-4907. PMID: 3459178. (Original… PMID 3459178 | mechanism / discovery |
| 2026 | IGF-1 DES | WADA. 2026 World Anti-Doping Code Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. (IGF-1 and analogs class prohibition.) | regulatory / registry |
| 2005 | IGF-1 DES | U.S. Food and Drug Administration. Increlex (mecasermin) Prescribing Information. Ipsen Biopharmaceuticals. First approved 2005. (Context: FDA-approved recombinant native IGF-1 — different molecule from IGF-1 DES.) | regulatory / registry |
| 2012 | IGF-1 DES | Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-169. PMID: 22473468. (IGF-1 pathway and cancer epidemiology — central class-level safety framing.) PMID 22473468 | research article |
| 2003 | IGF-1 DES | LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127-137. PMID: 12767520. PMID 12767520 | research article |
| 2001 | IGF-1 DES | Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2):195-200. PMID: 11175789. (Foundational muscle-s… PMID 11175789 | research article |
Related pair pages
More research context
Frequently asked
Have BPC-157 and IGF-1 DES been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 and IGF-1 DES. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 and IGF-1 DES share?
BPC-157 and IGF-1 DES do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 and IGF-1 DES?
BPC-157: Category 2 (reclassification pending). IGF-1 DES: Not approved; research only. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 and IGF-1 DES?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 profile and the IGF-1 DES profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026